TY - JOUR
T1 - Safety and Efficacy of CLS-TA by Anatomic Location of Inflammation
T2 - Results from the Phase 3 PEACHTREE Clinical Trial
AU - Shah, Milan
AU - Albini, Thomas
AU - Nguyen, Quan
AU - Wykoff, Charles
AU - Barakat, Mark
AU - Khurana, Rahul
AU - Kapik, Barry
AU - Ciulla, Thomas A.
N1 - Publisher Copyright:
© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.
PY - 2024
Y1 - 2024
N2 - Purpose: To explore the efficacy of CLS-TA, a proprietary suprachoroidal injectable suspension of triamcinolone acetonide, in noninfectious uveitis (NIU) with macular edema (ME), categorized by anatomic subtype. Methods: Patients diagnosed with ME associated with NIU of any etiology and anatomic subtype were eligible for the phase 3 PEACHTREE trial of CLS-TA. Post-hoc analyses were performed, stratified by discrete anatomic subtype of uveitis (anterior, intermediate, posterior, and panuveitis.) Results: Across all anatomic subtypes at 24 weeks, patients receiving CLS-TA at baseline and week 12 demonstrated mean increases in BCVA ranging from +12.1 to +15.9 letters, mean central subfield thickness (CST) improvement ranging from −120.1 µm to −189.0 µm, and IOP changes ranging from +0.5 to +3.1 mmHg. Overall, reports of adverse events were similar among subtypes. Conclusions: Irrespective of the uveitic anatomic subtype among patients treated for ME associated with NIU, a clinical benefit in participants treated with CLS-TA was demonstrated, with a comparable safety profile.
AB - Purpose: To explore the efficacy of CLS-TA, a proprietary suprachoroidal injectable suspension of triamcinolone acetonide, in noninfectious uveitis (NIU) with macular edema (ME), categorized by anatomic subtype. Methods: Patients diagnosed with ME associated with NIU of any etiology and anatomic subtype were eligible for the phase 3 PEACHTREE trial of CLS-TA. Post-hoc analyses were performed, stratified by discrete anatomic subtype of uveitis (anterior, intermediate, posterior, and panuveitis.) Results: Across all anatomic subtypes at 24 weeks, patients receiving CLS-TA at baseline and week 12 demonstrated mean increases in BCVA ranging from +12.1 to +15.9 letters, mean central subfield thickness (CST) improvement ranging from −120.1 µm to −189.0 µm, and IOP changes ranging from +0.5 to +3.1 mmHg. Overall, reports of adverse events were similar among subtypes. Conclusions: Irrespective of the uveitic anatomic subtype among patients treated for ME associated with NIU, a clinical benefit in participants treated with CLS-TA was demonstrated, with a comparable safety profile.
KW - Non-infectious Uveitis
KW - suprachoroidal injection
KW - triamcinolone Acetonide
KW - uveitic Macular Edema
UR - http://www.scopus.com/inward/record.url?scp=85181726897&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85181726897&partnerID=8YFLogxK
U2 - 10.1080/09273948.2023.2262015
DO - 10.1080/09273948.2023.2262015
M3 - Article
AN - SCOPUS:85181726897
SN - 0927-3948
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
ER -